| Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype (NCT05951205) | Vertex Pharmaceuticals Incorporated | 2027-07-31 |
| A Phase 1, First-in-human Study of VX-433 (NCT07584434) | Vertex Pharmaceuticals Incorporated | 2026-05-21 |
| A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis (NCT07501702) | Vertex Pharmaceuticals Incorporated | 2026-05-13 |
| Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants (NCT07570069) | Vertex Pharmaceuticals Incorporated | 2026-05-07 |
| Evaluation of Pain Treatment After Total Knee Arthroplasty (NCT07538570) | Vertex Pharmaceuticals Incorporated | 2026-04-24 |
| Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants (NCT07437105) | Vertex Pharmaceuticals Incorporated | 2026-02-25 |
| Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants (NCT07378865) | Vertex Pharmaceuticals Incorporated | 2026-02-13 |
| Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants (NCT07349394) | Vertex Pharmaceuticals Incorporated | 2026-01-12 |
| Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants (NCT07283770) | Vertex Pharmaceuticals Incorporated | 2025-12-09 |
| Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) (NCT07161037) | Vertex Pharmaceuticals Incorporated | 2025-11-19 |
| Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) (NCT07204275) | Vertex Pharmaceuticals Incorporated | 2025-09-30 |
| Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (NCT07074327) | Vertex Pharmaceuticals Incorporated | 2025-07-11 |
| A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations (NCT07010406) | Vertex Pharmaceuticals Incorporated | 2025-06-06 |
| A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I (NCT06926621) | Vertex Pharmaceuticals Incorporated | 2025-04-28 |
| A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation (NCT06861413) | Vertex Pharmaceuticals Incorporated | 2025-04-01 |
| An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant (NCT06832410) | Vertex Pharmaceuticals Incorporated | 2025-03-31 |
| A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries (NCT06887959) | Vertex Pharmaceuticals Incorporated | 2025-03-27 |
| A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries (NCT06887972) | Vertex Pharmaceuticals Incorporated | 2025-03-21 |
| A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose (NCT06886269) | Vertex Pharmaceuticals Incorporated | 2025-03-21 |
| A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists (NCT06834009) | Vertex Pharmaceuticals Incorporated | 2025-03-10 |
| Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants (NCT06820307) | Vertex Pharmaceuticals Incorporated | 2025-02-25 |
| Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities (NCT06794996) | Vertex Pharmaceuticals Incorporated | 2025-02-04 |
| Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (NCT06747572) | Vertex Pharmaceuticals Incorporated | 2024-12-19 |
| Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) (NCT06696443) | Vertex Pharmaceuticals Incorporated | 2024-12-18 |
| Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older (NCT06460506) | Vertex Pharmaceuticals Incorporated | 2024-11-21 |
| A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy (NCT06619847) | Vertex Pharmaceuticals Incorporated | 2024-10-29 |
| Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (NCT06619860) | Vertex Pharmaceuticals Incorporated | 2024-10-18 |
| Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (NCT06628908) | Vertex Pharmaceuticals Incorporated | 2024-10-01 |
| A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants (NCT06615570) | Vertex Pharmaceuticals Incorporated | 2024-09-30 |
| Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment (NCT06529796) | Vertex Pharmaceuticals Incorporated | 2024-08-02 |
| Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults (NCT06523595) | Vertex Pharmaceuticals Incorporated | 2024-07-31 |
| A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 (NCT06508762) | Vertex Pharmaceuticals Incorporated | 2024-07-26 |
| Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF) (NCT06506773) | Vertex Pharmaceuticals Incorporated | 2024-07-09 |
| A Microneurography Study of NaV1.8 Inhibition in Healthy Adults (NCT06420765) | Vertex Pharmaceuticals Incorporated | 2024-05-21 |
| A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults (NCT06392659) | Vertex Pharmaceuticals Incorporated | 2024-05-02 |
| A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants (NCT06345755) | Vertex Pharmaceuticals Incorporated | 2024-04-17 |
| A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation (NCT06312787) | Vertex Pharmaceuticals Incorporated | 2024-04-02 |
| A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine (NCT06336096) | Vertex Pharmaceuticals Incorporated | 2024-03-28 |
| A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists (NCT06299696) | Vertex Pharmaceuticals Incorporated | 2024-03-26 |
| A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (NCT06185764) | Vertex Pharmaceuticals Incorporated | 2024-02-20 |
| A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993 (NCT06226454) | Vertex Pharmaceuticals Incorporated | 2024-01-04 |
| Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) (NCT06176196) | Vertex Pharmaceuticals Incorporated | 2023-12-13 |
| Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (NCT06154447) | Vertex Pharmaceuticals Incorporated | 2023-12-12 |
| Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older (NCT05844449) | Vertex Pharmaceuticals Incorporated | 2023-08-11 |
| A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 (NCT05955872) | Vertex Pharmaceuticals Incorporated | 2023-07-19 |
| Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age (NCT05882357) | Vertex Pharmaceuticals Incorporated | 2023-06-27 |
| A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment (NCT05865171) | Vertex Pharmaceuticals Incorporated | 2023-06-12 |
| A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes (NCT05791201) | Vertex Pharmaceuticals Incorporated | 2023-05-16 |
| A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548 (NCT05851157) | Vertex Pharmaceuticals Incorporated | 2023-05-03 |
| A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants (NCT05818852) | Vertex Pharmaceuticals Incorporated | 2023-04-12 |
| A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) (NCT05668741) | Vertex Pharmaceuticals Incorporated | 2023-02-27 |
| Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment (NCT05704556) | Vertex Pharmaceuticals Incorporated | 2023-02-27 |
| A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype (NCT05643495) | Vertex Pharmaceuticals Incorporated | 2023-02-23 |
| A Phase 1, First-in-human Study of VX-668 (NCT05727800) | Vertex Pharmaceuticals Incorporated | 2023-02-08 |
| A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain (NCT05661734) | Vertex Pharmaceuticals Incorporated | 2023-01-09 |
| Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) (NCT05660538) | Vertex Pharmaceuticals Incorporated | 2022-12-20 |
| Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants (NCT05635110) | Vertex Pharmaceuticals Incorporated | 2022-12-15 |
| A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants (NCT05653323) | Vertex Pharmaceuticals Incorporated | 2022-12-14 |
| Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del (NCT05331183) | Vertex Pharmaceuticals Incorporated | 2022-11-23 |
| A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy (NCT05444257) | Vertex Pharmaceuticals Incorporated | 2022-11-08 |
| Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment (NCT05560464) | Vertex Pharmaceuticals Incorporated | 2022-10-14 |
| A Phase 1, First-in-human Study of VX-634 (NCT05579431) | Vertex Pharmaceuticals Incorporated | 2022-10-13 |
| Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty (NCT05558410) | Vertex Pharmaceuticals Incorporated | 2022-10-10 |
| Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy (NCT05553366) | Vertex Pharmaceuticals Incorporated | 2022-10-03 |
| A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin (NCT05541471) | Vertex Pharmaceuticals Incorporated | 2022-09-22 |
| A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants (NCT05518734) | Vertex Pharmaceuticals Incorporated | 2022-09-17 |
| A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor (NCT05535959) | Vertex Pharmaceuticals Incorporated | 2022-09-15 |
| Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease (NCT05477563) | Vertex Pharmaceuticals Incorporated | 2022-08-02 |
| Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment (NCT05437120) | Vertex Pharmaceuticals Incorporated | 2022-07-22 |
| A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548 (NCT05455502) | Vertex Pharmaceuticals Incorporated | 2022-07-13 |
| Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age (NCT05422222) | Vertex Pharmaceuticals Incorporated | 2022-06-21 |
| A Microneurography (MNG) Study of VX-150 in Healthy Participants (NCT05418712) | Vertex Pharmaceuticals Incorporated | 2022-06-16 |
| Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation (NCT05274269) | Vertex Pharmaceuticals Incorporated | 2022-05-09 |
| Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) (NCT05356195) | Vertex Pharmaceuticals Incorporated | 2022-05-03 |
| Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) (NCT05329649) | Vertex Pharmaceuticals Incorporated | 2022-05-02 |
| A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants (NCT05347394) | Vertex Pharmaceuticals Incorporated | 2022-04-08 |
| A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants (NCT05324410) | Vertex Pharmaceuticals Incorporated | 2022-04-07 |
| Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease (NCT05312879) | Vertex Pharmaceuticals Incorporated | 2022-03-30 |
| Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older (NCT05153317) | Vertex Pharmaceuticals Incorporated | 2022-01-17 |
| A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF) (NCT05111145) | Vertex Pharmaceuticals Incorporated | 2022-01-14 |
| A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation (NCT05076149) | Vertex Pharmaceuticals Incorporated | 2021-10-27 |
| A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) (NCT04969224) | Vertex Pharmaceuticals Incorporated | 2021-10-12 |
| A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) (NCT05033080) | Vertex Pharmaceuticals Incorporated | 2021-09-14 |
| A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty (NCT05034952) | Vertex Pharmaceuticals Incorporated | 2021-08-30 |
| A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy (NCT04977336) | Vertex Pharmaceuticals Incorporated | 2021-07-19 |
| A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis (NCT04923464) | Vertex Pharmaceuticals Incorporated | 2021-06-30 |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (NCT04786262) | Vertex Pharmaceuticals Incorporated | 2021-03-29 |
| A Long-term Follow-up Study in Participants Who Received CTX001 (NCT04208529) | Vertex Pharmaceuticals Incorporated | 2021-01-20 |
| A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) (NCT04599465) | Vertex Pharmaceuticals Incorporated | 2021-01-15 |
| A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes (NCT04545515) | Vertex Pharmaceuticals Incorporated | 2021-01-11 |
| Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years (NCT04537793) | Vertex Pharmaceuticals Incorporated | 2020-11-19 |
| Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype (NCT04474197) | Vertex Pharmaceuticals Incorporated | 2020-07-24 |
| A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes (NCT04353817) | Vertex Pharmaceuticals Incorporated | 2020-06-19 |
| Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis (NCT04340362) | Vertex Pharmaceuticals Incorporated | 2020-06-08 |
| A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy (NCT04362761) | Vertex Pharmaceuticals Incorporated | 2020-05-04 |
| Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older (NCT04183790) | Vertex Pharmaceuticals Incorporated | 2020-02-17 |
| Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype (NCT04167345) | Vertex Pharmaceuticals Incorporated | 2020-01-13 |
| Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy (NCT04058366) | Vertex Pharmaceuticals Incorporated | 2019-12-05 |
| A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del (NCT04105972) | Vertex Pharmaceuticals Incorporated | 2019-10-03 |
| A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) (NCT04058353) | Vertex Pharmaceuticals Incorporated | 2019-08-28 |